204 related articles for article (PubMed ID: 25224353)
1. Use of proton pump inhibitors as adjunct treatment for triple-negative breast cancers. An introductory study.
Goh W; Sleptsova-Freidrich I; Petrovic N
J Pharm Pharm Sci; 2014; 17(3):439-46. PubMed ID: 25224353
[TBL] [Abstract][Full Text] [Related]
2. Small Molecular Leads Differentially Active Against HER2 Positive and Triple Negative Breast Cancer Cell Lines.
Badran A; Atia-Tul-Wahab ; Fayyaz S; Baydoun E; Choudhary MI
Med Chem; 2019; 15(7):738-742. PubMed ID: 30398120
[TBL] [Abstract][Full Text] [Related]
3. Synergistic effect of photodynamic treatment and doxorubicin on triple negative breast cancer cells.
Yousefi Sadeghloo A; Khorsandi K; Kianmehr Z
Photochem Photobiol Sci; 2020 Nov; 19(11):1580-1589. PubMed ID: 33030191
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic efficacy of proton transport inhibitors alone or in combination with cisplatin in triple negative and hormone sensitive breast cancer models.
Balza E; Carlone S; Carta S; Piccioli P; Cossu V; Marini C; Sambuceti G; Rubartelli A; Castellani P
Cancer Med; 2022 Jan; 11(1):183-193. PubMed ID: 34796694
[TBL] [Abstract][Full Text] [Related]
5. Dual-targeted hybrid nanoparticles of synergistic drugs for treating lung metastases of triple negative breast cancer in mice.
Zhang T; Prasad P; Cai P; He C; Shan D; Rauth AM; Wu XY
Acta Pharmacol Sin; 2017 Jun; 38(6):835-847. PubMed ID: 28216624
[TBL] [Abstract][Full Text] [Related]
6. Proton Pump Inhibition Enhances the Cytotoxicity of Paclitaxel in Cervical Cancer.
Song T; Jeon HK; Hong JE; Choi JJ; Kim TJ; Choi CH; Bae DS; Kim BG; Lee JW
Cancer Res Treat; 2017 Jul; 49(3):595-606. PubMed ID: 27669706
[TBL] [Abstract][Full Text] [Related]
7. Inhibiting epidermal growth factor receptor signalling potentiates mesenchymal-epithelial transition of breast cancer stem cells and their responsiveness to anticancer drugs.
Manupati K; Dhoke NR; Debnath T; Yeeravalli R; Guguloth K; Saeidpour S; De UC; Debnath S; Das A
FEBS J; 2017 Jun; 284(12):1830-1854. PubMed ID: 28398698
[TBL] [Abstract][Full Text] [Related]
8. Exploring the Molecular Mechanism of Cinnamic Acid-Mediated Cytotoxicity in Triple Negative MDA-MB-231 Breast Cancer Cells.
Pal A; Tapadar P; Pal R
Anticancer Agents Med Chem; 2021; 21(9):1141-1150. PubMed ID: 32767960
[TBL] [Abstract][Full Text] [Related]
9. Proton pump inhibitors (PPIs) impact on tumour cell survival, metastatic potential and chemotherapy resistance, and affect expression of resistance-relevant miRNAs in esophageal cancer.
Lindner K; Borchardt C; Schöpp M; Bürgers A; Stock C; Hussey DJ; Haier J; Hummel R
J Exp Clin Cancer Res; 2014 Sep; 33(1):73. PubMed ID: 25175076
[TBL] [Abstract][Full Text] [Related]
10. Identification of Novel Bisbenzimidazole Derivatives as Anticancer Vacuolar (H⁺)-ATPase Inhibitors.
Patil R; Kulshrestha A; Tikoo A; Fleetwood S; Katara G; Kolli B; Seibel W; Gilman-Sachs A; Patil SA; Beaman KD
Molecules; 2017 Sep; 22(9):. PubMed ID: 28926955
[TBL] [Abstract][Full Text] [Related]
11. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.
Vázquez R; Riveiro ME; Astorgues-Xerri L; Odore E; Rezai K; Erba E; Panini N; Rinaldi A; Kwee I; Beltrame L; Bekradda M; Cvitkovic E; Bertoni F; Frapolli R; D'Incalci M
Oncotarget; 2017 Jan; 8(5):7598-7613. PubMed ID: 27935867
[TBL] [Abstract][Full Text] [Related]
12. Diterpenoid natural compound C4 (Crassin) exerts cytostatic effects on triple-negative breast cancer cells via a pathway involving reactive oxygen species.
Richards CE; Vellanki SH; Smith YE; Hopkins AM
Cell Oncol (Dordr); 2018 Feb; 41(1):35-46. PubMed ID: 29134467
[TBL] [Abstract][Full Text] [Related]
13. The Application of Non-Invasive Apoptosis Detection Sensor (NIADS) on Histone Deacetylation Inhibitor (HDACi)-Induced Breast Cancer Cell Death.
Hsu KW; Huang CY; Tam KW; Lin CY; Huang LC; Lin CL; Hsieh WS; Chi WM; Chang YJ; Wei PL; Chen ST; Lee CH
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29393914
[TBL] [Abstract][Full Text] [Related]
14. A novel compound LingH2-10 inhibits the growth of triple negative breast cancer cells in vitro and in vivo as a selective inverse agonist of estrogen-related receptor α.
Ning Y; Chen H; Du Y; Ling H; Zhang L; Chen L; Qi H; Shi X; Li Q
Biomed Pharmacother; 2017 Sep; 93():913-922. PubMed ID: 28715872
[TBL] [Abstract][Full Text] [Related]
15. Effects of esomeprazole on healing of nonsteroidal anti-inflammatory drug (NSAID)-induced gastric ulcers in the presence of a continued NSAID treatment: Characterization of molecular mechanisms.
Fornai M; Colucci R; Antonioli L; Awwad O; Ugolini C; Tuccori M; Fulceri F; Natale G; Basolo F; Blandizzi C
Pharmacol Res; 2011 Jan; 63(1):59-67. PubMed ID: 20969958
[TBL] [Abstract][Full Text] [Related]
16. Combining naringenin and metformin with doxorubicin enhances anticancer activity against triple-negative breast cancer in vitro and in vivo.
Pateliya B; Burade V; Goswami S
Eur J Pharmacol; 2021 Jan; 891():173725. PubMed ID: 33157041
[TBL] [Abstract][Full Text] [Related]
17. Discovery and SAR studies of novel 2-anilinopyrimidine-based selective inhibitors against triple-negative breast cancer cell line MDA-MB-468.
Jo J; Kim SH; Kim H; Jeong M; Kwak JH; Taek Han Y; Jeong JY; Jung YS; Yun H
Bioorg Med Chem Lett; 2019 Jan; 29(1):62-65. PubMed ID: 30447889
[TBL] [Abstract][Full Text] [Related]
18. Effect of metformin on estrogen and progesterone receptor-positive (MCF-7) and triple-negative (MDA-MB-231) breast cancer cells.
Amaral I; Silva C; Correia-Branco A; Martel F
Biomed Pharmacother; 2018 Jun; 102():94-101. PubMed ID: 29550639
[TBL] [Abstract][Full Text] [Related]
19. [10]-Gingerol improves doxorubicin anticancer activity and decreases its side effects in triple negative breast cancer models.
Baptista Moreno Martin AC; Tomasin R; Luna-Dulcey L; Graminha AE; Araújo Naves M; Teles RHG; da Silva VD; da Silva JA; Vieira PC; Annabi B; Cominetti MR
Cell Oncol (Dordr); 2020 Oct; 43(5):915-929. PubMed ID: 32761561
[TBL] [Abstract][Full Text] [Related]
20. Metastatic triple-negative breast cancer is dependent on SphKs/S1P signaling for growth and survival.
Maiti A; Takabe K; Hait NC
Cell Signal; 2017 Apr; 32():85-92. PubMed ID: 28108260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
